PDA Southeast Chapter’s Post

If you or anyone you know is looking for some lab space to jumpstart your research, please reach out! ABI Lab is the place to be ✨ If you don’t believe me, check out this most recent news letter by MetroWest Daily News!

A tale of perseverance and strategy at 2seventy bio. In just two years, the biotech has weathered layoffs, pipeline reorganizations, fierce competition, FDA safety warnings, and discontinued clinical trials. Yet, CEO Chip Baird credits transparency and a committed staff for keeping the company afloat. Despite the challenges, 2seventy is now on the path to profitability, with Baird predicting reaching that milestone next year. Stay tuned for potential growth strategies once breakeven is achieved. #biotech #perseverance #strategy #celltherapy #CarT #multiplemyeloma #advancedtherapies #regenerativemedicine #lifescience #lifesciences #biotech #biotechnology bluebird bio #milestones #profitability

Next: readoud of randomized controlled phase 2b and phase 3 clinical trials of CAN-2409 in early, localized, non-metastatic prostate cancer this year.

Every small action that we take can have a major impact on the environment. At Caplin, through our ESG practices, we care about the environment and commit to preserve it today for a better tomorrow. #caplinpointlaboratories #caplinpoint #caplinsteriles #caplinonelabs #caplinone #sterilemanufacturing #caplincares #caplinwishes #pharmamanufacturing #injectables #formulations #RandD #worldenvironmentday #environmentday #solidorals #cancertreatment #oncology #affordablehealthcareforall

📊 In the age of huge data sets, AI and innovative chemistry, how do you decide which molecules from your vast libraries have potential early on? 🔬When cell culture doesn’t provide the context of a complex biological system and organoids aren’t scalable enough, how do you bridge the gap between in vitro and mammals? 💡What if you could screen hundreds of thousands of compounds in vivo within weeks for a few £s per compound? 📍Come and visit our booth in the breakthrough zone - BZ10 - to find out more #elrig #elrigdd24 #drugdiscovery #HTS

In collaboration with Columbia University, Silo Pharma is creating SPC-14, a novel drug combining two approved therapeutics to target #AlzheimersDisease. With initial positive results from animal studies and more data expected in 2024, Silo believes SPC-14 represents an encouraging development in Alzheimer’s disease research. Two formulations of SPC-14 are currently in development, one with #ketamine and one without. Take a deeper dive: https://bit.ly/3ZCE0hY #Science #Biotech #Psychedelics #PsychedelicResearch #ADResearch

Congratulations to Srijan and PhenUtest Diagnostics team for being named a nominee of Bionow Start-up Award 2023! PhenUtest Diagnostics is a diagnostic company revolutionising the diagnosis and treatment of urinary tract infections (#uti). It is developing an innovative point-of-care test to give results in under an hour including a full antimicrobial susceptibility test. Ground-breaking technology with the potential to transform the diagnosis and treatment of urinary tract infection, a common condition associated with billions of dollars of annual healthcare costs globally. In the US alone these costs are in the order of $44bn. University of Liverpool | Research, Partnerships and Innovation Faculty of Health & Life Sciences, University of Liverpool Carolyn Horrocks Alison Pountney #universityspinouts #innovation #urinarytractinfection

Meet our founders! 1cBio was founded in 2022 by Jit Chakravarty, Sunny Chen, and Son Pham. Their collaborative journey began almost a decade ago at Medivation, where Jit played a key role in the development and approval of XTANDI® (enzalutamide), while Sunny was part of the team that helped develop TALZENNA®️ (talazoparib). SPARCBIO emerged following Pfizer’s acquisition of Medivation, and as co-workers evolved into first-time entrepreneurs, they fostered a collective synergy in their ability to transform inventions into innovations and build companies with sustainable portfolios. Through countless late-night conference calls, working dinners, and long flights, Jit, Sunny, Son, and their dedicated team developed and supported five unique small-molecule programs. Their efforts resulted in four clinical candidates between 2016 and 2022. In 2019, SPARCBIO's assets were sold in a transaction involving cash and stock, laying the foundation for a new public company (NYSE: NUVB). With an amalgamation of experiences, both personal and professional, the team at 1cBio is driven by their common desire to positively impact patients' lives. These efforts continue to propel the company forward as a clinical-stage enterprise. To learn more visit: www.1cbio.com #FoundingStory #1cBio #Our1cause #DrugDiscovery #DrugDevelopment #BioPharma #Oncology #RareDisease #HPP

Exciting news as BioTryp Therapeutics, an award-winning drug discovery spin-out from the University of Cambridge, has raised £300k in pre-seed funding to advance its novel anti-biofilm compounds 🦠   Amanda Wooding, Deputy Head of Cambridge Enterprise Ventures, said “Congratulations to BioTryp Therapeutics for securing this investment during their participation in the Start 1.0 cohort of Founders at the University of Cambridge. It’s fantastic to be part of their journey. Enabling companies like BioTryp to address significant unmet needs for the benefit of society is at the core of Cambridge Enterprise Ventures activities, providing patient capital from the University of Cambridge balance sheet to unlock syndicated investments.”   BioTryp Therapeutics is developing novel anti-biofilm drugs to tackle recurrent biofilm-associated infections, aiming to revolutionize the management and treatment of bacterial infections and support global efforts against the rising ineffectiveness of traditional antibiotics 💊   This funding round was supported by QUBIS Ltd Innovation Fund, Parkwalk Advisors and Cambridge Enterprise Ventures.   Click here to find out more about BioTryp and their recent funding round: https://lnkd.in/e9wXXZ47 #CambridgeInnovation #Biofilms #Biotechnology #DrugDiscovery

What's fascinating about the world of ants is not just that they can triage their injured, but they carry many antimicrobial proteins in their metapleural glands. For us, at GoldBio, we get excited when new antimicrobials have been discovered because it can potentially open the world of therapeutics. Learn more about this discovery and more here: https://lnkd.in/ghz5aAW9